Skip Ribbon Commands
Skip to main content

Dr Ng Kok Pin

Dr Ng Kok Pin

​MBBS (Singapore), MRCP (United Kingdom), MCI (NUS)


National Neuroscience Institute

Specialty: Neurology, Neuroscience

Sub-specialties: Cognitive Neurology

Conditions Treated by this Doctor:
General Neurology.

Clinical Appointments

  • Service Chief SingHealth Duke-NUS Centre of Memory and Cognitive Disorders
  • Consultant Department of Neurology National Neuroscience InstituteNational Neuroscience Institute


Dr Ng Kok Pin is a Consultant at the Department of Neurology, National Neuroscience Institute. After graduating from the Yong Loo Lin School of Medicine, National University of Singapore in 2006, he obtained his MRCP(UK) in 2011 and was accredited as a Neurologist by the Ministry of Health Singapore in 2015. In 2016, he obtained his Master of Clinical Investigation (NUS).

Dr Ng subspecialises in dementia and his research interest is PET imaging in neurocognitive diseases. He completed his 1-year clinical research fellowship at the McGill University Research Centre for Studies in Aging, Montreal, Canada in 2017.


MCI (NUS), 2015

MRCP (UK), 2011

MBBS National University of Singapore, 2006

Professional Appointments and Committee Memberships

  • Consultant, Department of Neurology, National Neuroscience Institute, 2017 - Present
  • Clinical Lecturer, Yong Loo Lin School of Medicine (NUS)
  • Teaching Faculty, NTU Lee Kong Chian Medicine School of Medicine


  • NMRC Research Training Fellowship, 2016
  • MOH Healthcare Research Scholarship, 2014

Research Interests

  • Alzheimer’s dementia
  • PET imaging in dementia


  • ​Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., et al. 2017. Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology, 88(19), pp.1814-1821.
  • Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., Therriault, J., Kang, M.S., Shin, M., Guiot, M.C., Guo, Q., Harada, R., Comley, R.A. and Massarweh, G., 2017. Monoamine oxidase B inhibitor, selegiline, reduces 18 F-THK5351 uptake in the human brain. Alzheimer's Research & Therapy, 9(1), p.25.
  • Li, X., Ba, M., Ng, K.P., Mathotaarachchi, S., Pascoal, T.A., Rosa-Neto, P., Gauthier, S. and Alzheimer's Disease Neuroimaging Initiative, 2017. Characterizing biomarker features of cognitively normal individuals with ventriculomegaly. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.
  • Ng, K.P., Ng, A., Assam, P., Heng, E. and Kandiah, N., 2014. Role of cognitive enhancer therapy in Alzheimer’s disease with concomitant cerebral white matter disease: findings from a long-term naturalistic study. Drugs in R&d, 14(3), pp.195-203.
  • Ba, M., Li, X., Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., Rosa-Neto, P., Gauthier, S. and Alzheimer's Disease Neuroimaging Initiative, 2017. The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 3(1), pp.107-113.
  • Ba, M., Kong, M., Li, X., Ng, K.P., Rosa-Neto, P. and Gauthier, S., 2016. Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?. Translational Neurodegeneration, 5(1), p.20.

Research Trials